Table 25:
Quality of Life Score After Cyanoacrylate Adhesive Closure vs. Radiofrequency Ablation
| Author, Year (Study Design) | Baseline Score, MN (SD)a | Follow-Up Time Point | Follow-Up Score, MN (SD)a | P Value | ||
|---|---|---|---|---|---|---|
| CAC | RFA | CAC | RFA | |||
| Disease-Specific Quality of Life: Aberdeen Varicose Vein Questionnaire | ||||||
| VeClose trial70–72,81 (RCT, noninferiority trial) |
18.9 (9.0) | 19.4 (9.9) | 1 mo70 | 11.9 (7.1) | 12.6 (8.3) | 0.53b |
| 3 mo70 | 11.6 (7.5) | 10.7 (8.6) | ||||
| 6 mo72 | 10.2c(5.6c) | 9.1c (7.1c) | NS (NR) | |||
| 12 mo72 | 9.7c (7.1c) | 8.4c (6.5c) | NS (NR) | |||
| 24 mo72 | 8.2c (7.9c) | 8.3c (7.5c) | NS (NR) | |||
| 36 mo72 | 7.3c (6.4c) | 8.2c (7.8c) | NS (NR) | |||
| 60 mo81 | 8.3 (9.6d) | 6.6 (5.7d) | .3418 | |||
| Ovali and Sevin, 201966 (prospective comparative cohort) | 17.43 (6.38) | 18.21 (6.93) | 12 mo | 4.93 (1.56) | 5.13 (1.49) | .752 |
| Bademci et al, 201964 (prospective comparative cohort) |
MD 17 (range 15–21) | 17 (11–21) | 1 mo | 7 (6–9) | 8 (5–13) | .10 |
| 6 mo | 5 (4–7) | 6 (3–10) | .84 | |||
| 12 mo | 4 (3–6) | 4 (1–9) | .61 | |||
| Generic Quality of Life: EQ-5D TTO | ||||||
| VeClose trial70,81 (RCT, noninferiority trial) | 0.935 (.113) | 0.918 (.116) | 1 mo70 | 0.965 (.113) | 0.961 (.106) | .34b |
| 3 mo70 | .965 (.095) | .965 (.083) | ||||
| 60 mo81 | 0.97 (.08) | .94 (.11) | NR | |||
Abbreviations: CAC, cyanoacrylate adhesive closure; EQ-5D TTO, EuroQol 5-Dimension Time Trade Off; MD, median; MN, mean; mo, month(s); NR, not reported; NS, not significant; RCT, randomized controlled trial; RFA, radiofrequency ablation; SD, standard deviation.
Unless otherwise noted values are mean and standard deviation.
Repeated-measures ANOVA comparing baseline, 1 mo, and 3 mo.70